<a href="https://www.fiercebiotech.com/biotech/which-blockbuster-gsk-gunning-next-ceo-miels-points-looking-oncology" hreflang="en">Which blockbuster is GSK gunning for next? CEO Miels is looking to oncology</a>
GSK's CEO Luke Miels is focusing on oncology for future acquisitions, seeking to improve upon existing treatments in established areas, as evidenced by recent deals including the $2.2 billion buyout of Rapt Therapeutics and a $950 million acquisition of 35Pharma. Miels emphasizes a strategy of identifying opportunities within GSK's portfolio to accelerate existing programs and explore new indications.
GSK's CEO Luke Miels is focusing on oncology as a strategic area for blockbuster drug development, aiming to improve on existing treatments where the science is "reasonably established." This approach, which includes recent acquisitions like Rapt Therapeutics and IDRx, highlights potential investment opportunities in companies with established but sub-optimal treatment options in oncology, cardiovascular, and respiratory fields. For an investor or entrepreneur in healthtech and biotech, targeting innovations that enhance or replace current blockbusters in these areas could align with GSK's growth strategy.